Advances in the Management of Cystic
Fibrosis: A Closer
Look at the Roles of CFTR Modulation Therapy
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from January 15, 2017 to January 31, 2018
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate. To print or save your certificate, you will need
to click on the “download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This activity is supported by
an educational grant from
According to the Cystic Fibrosis (CF) Foundation, about 30,000
people are currently living with cystic fibrosis, and approximately
1,000 new cases of CF are diagnosed each year. There is no cure for
cystic fibrosis, but recent treatment breakthroughs have the ability
to provide a greater quality of life and improved outcomes for
patients with CF. CF is an autosomal recessive disorder, caused by
the presence of mutations in both copies of the gene for the protein
cystic fibrosis transmembrane conductance regulator (CFTR).
Fortunately for about half of CF patients, a new treatment is
available for those who have two copies of the F508del mutation in
their CFTR gene. This new CFTR modulation therapeutic focuses on
counteracting the damage caused by the disease, enabling patients to
breathe more easily and stay out of the hospital, improving outcomes
and quality of life. This option is a major breakthrough in CF
management, because it is the first therapy that specifically
targets an important genetic mutation.
Upon Completion of this
activity, participants will be able to:
Assess newly approved and emerging
CFTR-targeted treatment strategies according to their mechanism
of action, efficacy, and safety
Examine the role of CFTR modulation
therapy in the treatment and management of cystic fibrosis
Discuss the importance of genetic
testing in suspected adult-onset CF
Analyze optimal strategies to manage
and monitor CFTR modulator-related adverse events in cystic
Explore strategies to employ a
multidisciplinary approach to management of the CF patient, and
communicate effectively with patients and their families about
the role of genetic analysis
||Susanna A. McColley, MD
Associate Chief Research Officer
Stanley Manne Children’s Research Institute
Associate Clinical Director for Child Health,
Northwestern University Clinical and Translational
Professor of Pediatrics, Northwestern University
Feinberg School of Medicine
Associate Director, Cystic Fibrosis Center
Division of Pulmonary Medicine
McColley serves as a consultant to AbbVie and Vertex
Pharmaceuticals. Her presentation has been peer
Bill Williams, MD has no real or perceived financial
relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or
perceived financial relationships to disclose.
Katie Eads has no real or perceived financial
relationships to disclose.
Will Williams has no real or perceived financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians is accredited by
the Accreditation Council for Continuing Medical Education to
provide continuing medical education to physicians.
The National Association of Managed Care Physicians designates this
live activity for a maximum of 1 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of
their participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing education by the American Nurses
Credentialing Center’s Commission on Accreditation. Nurses who
complete this activity and turn in a validation form will receive up
to 1 credit in continuing nursing education.
The American Board of Managed Care Nurses has approved this activity
for a maximum of 1 contact hour towards CMCN recertification.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is
supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue